Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:57:38.866Z.
Calculation as of: 2026-10-06T19:57:38.866Z.
Quote observation: 2026-10-06T19:55:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 04c3f12431ab3e8d6f15e27a04b3f35a1ccc42ae6fada6e5bc04b9c12e20bb1c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$17.14M
Price/FCF Ratio
N/A
TTM Avg
2103.03
3Y Avg
2594.52
5Y Avg
2594.52
Market Cap
$18.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.43M
Price/FCF Ratio
N/A
TTM Avg
43.53
3Y Avg
55.71
5Y Avg
97.87
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lipocine Inc. (LPCN) | $17.19M | N/A | N/A | N/A | N/A |
| PAVmed Inc. (PAVM)vs › | $17.20M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | N/A | 2103.03 | 2594.52 | 2594.52 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.77M | N/A | N/A | N/A | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.75M | N/A | N/A | N/A | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.18M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.43M | N/A | 43.53 | 55.71 | 97.87 |
| Cosmos Health Inc. (COSM)vs › | $17.32M | N/A | 14.41 | 40.25 | 40.25 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
